Steven Cohen’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-250,000
| Closed | -$55.2M | – | 3840 |
|
|
2025
Q4 | $55.2M | Sell |
250,000
-1,328,069
| -84% | -$215M | 0.06% | 362 |
|
|
2025
Q3 | $151M | Buy |
1,578,069
+50,139
| +3% | +$3.2M | 0.25% | 65 |
|
|
2025
Q2 | $74.4M | Buy |
1,527,930
+1,414,075
| +1,242% | +$34M | 0.15% | 166 |
|
|
2025
Q1 | $2.45M | Buy |
113,855
+107,707
| +1,752% | +$2.39M | 0.01% | 1183 |
|
|
2024
Q4 | $165K | Buy |
+6,148
| New | +$99.9K | ﹤0.01% | 1921 |
|
|
2024
Q2 | – | Sell |
-62,500
| Closed | -$1.15M | – | 1907 |
|
|
2024
Q1 | $1.15M | Hold |
62,500
| – | – | ﹤0.01% | 1437 |
|
|
2023
Q4 | $993K | Hold |
62,500
| – | – | ﹤0.01% | 1401 |
|
|
2023
Q3 | $1.18M | Hold |
62,500
| – | – | ﹤0.01% | 1281 |
|
|
2023
Q2 | $1.41M | Hold |
62,500
| – | – | ﹤0.01% | 1088 |
|
|
2023
Q1 | $1.59M | Sell |
62,500
-130,900
| -68% | -$3.71M | ﹤0.01% | 1024 |
|
|
2022
Q4 | $2.93M | Hold |
193,400
| – | – | 0.01% | 871 |
|
|
2022
Q3 | $2.43M | Sell |
193,400
-16,600
| -8% | -$229K | 0.01% | 886 |
|
|
2022
Q2 | $2.05M | Hold |
210,000
| – | – | 0.01% | 929 |
|
|
2022
Q1 | $3.5M | Hold |
210,000
| – | – | 0.01% | 775 |
|
|
2021
Q4 | $5.33M | Buy |
+210,000
| New | +$6.54M | 0.02% | 648 |
|
Steven Cohen's CDTX Position: Q1 2026 in Review
Steven Cohen sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 250,000 shares — an estimated $55.2M sold.
Steven Cohen first reported a position in CDTX in Q4 2021 and held it in 15 quarters. The position peaked at $151M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Steven Cohen reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Steven Cohen sold 250,000 Cidara Therapeutics shares in Q1 2026, an estimated $55.2M.
- Steven Cohen first reported a position in Cidara Therapeutics in Q4 2021 and held it in 15 quarters.
- Steven Cohen's Cidara Therapeutics position peaked at $151M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.